Glaukos Corporation GKOS NYSE

Glaukos Corporation (GKOS) reported total assets of $893.49M and total liabilities of $237.33M for fiscal year 2025, resulting in total equity of $656.16M.

The company held $278.76M in cash and short-term investments. Total debt stood at $139.64M, with net debt of $48.83M. The Debt-to-Equity (D/E) ratio was 0.21 (conservative).

Current ratio is 4.69, indicating strong short-term liquidity. Interest coverage is -43.1x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (55/100) — Total assets $893.49M and equity $656.16M support the company's competitive scale
• VALUE (92/100) — Debt-to-Equity 0.21 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 52/100 with 2/7 criteria passed.

ARWR

Arrowhead Pharmaceuticals, Inc.

$66.69

+4.55%

ACLX

Arcellx, Inc.

$114.89

+0.02%

BRKR

Bruker Corporation

$39.90

+2.18%

BLCO

Bausch + Lomb Corporation

$16.71

+0.54%

ALKS

Alkermes plc

$33.87

+0.36%

TFX

Teleflex Incorporated

$125.21

+1.65%

MMSI

Merit Medical Systems, Inc.

$70.54

-0.04%

IRTC

iRhythm Technologies, Inc.

$123.23

+2.31%